Waystar stock holds at USD 43.30 as growth remains central

Waystar stock (ISIN US94419L1017) was quoted at USD 43.30 on the Nasdaq on September 23, 2026. The company’s market capitalization stood at USD 7.1 billion on the same date, giving investors a current valuation reference while operating growth remains the central company metric.

Revenue reaches USD 1 billion

Waystar reported revenue of USD 1.0 billion for fiscal year 2025, a higher figure than the USD 873 million recorded in fiscal year 2024. The comparison represents growth of approximately 14.5 percent and shows the scale reached by the healthcare technology provider.

Adjusted EBITDA was USD 386 million in fiscal year 2025, compared with USD 315 million in fiscal year 2024. That increase of USD 71 million, or approximately 22.5 percent, was faster than revenue growth and points to operating leverage in the reported period.

Operating leverage shapes valuation

The relationship between revenue growth and adjusted EBITDA growth is the key numerical feature of the fiscal year 2025 results. EBITDA expanded by approximately 22.5 percent while revenue increased by approximately 14.5 percent, a difference of about 8 percentage points.

For investors, that spread matters because Waystar is valued not only on the expansion of its healthcare payments and technology platform, but also on the conversion of additional revenue into operating earnings. The USD 43.30 Nasdaq quotation on September 23, 2026 therefore provides the market reference for judging that earnings trajectory.

Stock remains tied to execution

Waystar stock closed at USD 43.30 on the Nasdaq as of September 23, 2026, while the company carried a USD 7.1 billion market capitalization. The dated price and valuation sit alongside the fiscal year 2025 revenue of USD 1.0 billion and adjusted EBITDA of USD 386 million.

More news and analyses on Waystar stock